Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to lower COVID-19 infections in the U.S. and a drop in purchases by governments. On the plus side ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.